Physician profile
Dhirendra Patel
NPI 1306837471
$19,009.39
in general payments reported to CMS, 2019-2025
61 companies · $3,135 in 2025
The $3,135 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,442 · 2020: $2,220 · 2021: $3,002 · 2022: $2,465 · 2023: $2,676 · 2024: $3,070 · 2025: $3,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,874 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,874.08 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,998.70 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,566.85 | 2019-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $1,475.45 | 2019-2025 | |
| Abbvie INC. | $1,465.14 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,176.31 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,152.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,147.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $1,074.76 | 2019-2025 | |
| Novo Nordisk INC | $1,066.77 | 2019-2025 | Wegovy, Ozempic |
| Astellas Pharma US INC | $578.81 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $552.34 | 2019-2022 | |
| Mylan Specialty L.P. | $464.63 | 2019-2024 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $450.13 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Neurocrine Biosciences, INC. | $443.34 | 2022-2025 | Ingrezza, Ongentys |
| E.R. Squibb & Sons, L.L.C. | $392.90 | 2019-2025 | Eliquis |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhirendra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.